Kiniksa Pharmaceuticals International PLC Class A

Kiniksa recorded in Q3, thanks to strong demand for Arcalyst, a revenue increase of about 58% and a rise in net profit from $18.4 million to $47.3 million, thereby beating analysts' expectations. Management under Ross Moat and a solid capital position are expected to support further market penetration and pipeline development. The stock appears poised for new highs. » More on finanzen.net

Kiniksa Pharmaceuticals International’s board has appointed Ross Moat as chief operating officer effective Friday; Moat will also remain responsible for commercial activities. Eben Tessari was named chief strategy officer and will continue to lead strategy, business development and technical operations as well as the company’s AI initiatives. Both appointments involve no changes to compensation arrangements; Kiniksa is headquartered in London and trades on Nasdaq under the ticker KNSA. » More on de.investing.com